Kusalic 1993.

Methods	6‐week, double‐blind study, number of study centres not reported, placebo lead‐in period of 1 week, exclusion of placebo responder not reported
Participants	Psychiatric outpatients meeting DSM‐III‐R criteria for major depressive episode, having a minimum score 18 of on the 17‐item HAM‐D Age: range (total) 22 to 61 years, mean (total) 41.3 ± 10.1 Sex: M24, F14 (total) Inclusion criteria: "Subjects were in good physical health according to physical examination, blood count, T3/4 laboratory and ECG"
Interventions	Amitriptyline: 13 participants Placebo: 15 participants Amitriptyline dose: mean 109.93 ± 5.11
Outcomes	Primary outcome: thyroid assay Secondary outcome: response
Notes	Sponsor: unclear Response: "improvement: 50% decline in the HRSD score by the end of the treatment period" Remission: no definition, no data 3‐arm study comparing amitriptyline, moclobemide and placebo (total 39 patients)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details presented, assumed because double‐blind trial
Allocation concealment (selection bias)	Unclear risk	Quote: “The medication was given in capsules that were identical in shape, size and color”, "double‐blind"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: “The medication was given in capsules that were identical in shape, size and color”, "double‐blind"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: “The medication was given in capsules that were identical in shape, size and color”, "double‐blind", no details on blinding of assessor
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Drop‐outs not presented, unclear whether there were any
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	There appear to be 2 typos about numbers, no obvious other bias